NCT05787756 (GUT-PD) is a clinical trial in Parkinson Disease, sponsored by University of Aberdeen.

Who is sponsoring NCT05787756?

NCT05787756 is sponsored by University of Aberdeen.

What condition does NCT05787756 study?

NCT05787756 studies Parkinson Disease.

Is NCT05787756 still recruiting?

NCT05787756 is currently status unknown. Last updated 12 April 2023.

Last reviewed 2023-04-12 · How we verify

NCT05787756: GUT-PD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Constipation and Changes in the Gut Flora in Parkinson's Disease

Status unknown Last updated 12 April 2023

What this trial tests

trial in Parkinson Disease in 80 participants. Status unknown.

Timeline

1 January 2023

Primary endpoint
30 August 2023

30 October 2023

Quick facts

Lead sponsor	University of Aberdeen
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	80
Start date	1 January 2023
Primary completion	30 August 2023
Estimated completion	30 October 2023
Sites	1 location across United Kingdom

Conditions studied

Parkinson Disease — all drugs for Parkinson Disease →

Sponsor

University of Aberdeen

Who can join

Adults 18 to 110, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to investigate the link between gut health and Parkinson's disease

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

From the Gut to the Brain: Is Microbiota a New Paradigm in Parkinson's Disease Treatment?
Vilela C, Araújo B, Soares-Guedes C, Caridade-Silva R, et al · · 2024 · cited 7× · PMID 38727306 · DOI 10.3390/cells13090770

Verify or expand the search:

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting

Other University of Aberdeen trials

Trials by the same sponsor.

NCT07070765 — Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity · NA · not yet recruiting
NCT07065383 — Rebalancing the Fat Content of the Heart and Muscles · NA · recruiting
NCT06735573 — Protein, Sarcopenic Obesity, and COPD · not yet recruiting
NCT06714656 — Drivers and Barriers for Adopting Healthy and Sustainable Food Swaps in Young · NA · recruiting
NCT06721312 — Continuous Heart Rate Variability Monitoring in Doctors; Understanding Patterns of Stress and Recovery and Their Relatio · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05787756 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Aberdeen
Last refreshed: 12 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05787756.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing